Previz Ventures

Previz Ventures is a venture capital firm located in Herzliya, Israel, established in 2012. The firm specializes in early-stage investments, focusing on technology-driven companies within the medical device and healthcare information and communications technology sectors. By targeting innovative startups in these fields, Previz Ventures aims to support the development of cutting-edge solutions that can enhance healthcare delivery and medical practices.

Eliav Azulay-Oz

Co-Founder and Managing Partner

Dan Baruchi

Managing Partner

4 past transactions

ClearCount Medical Solutions specializes in patient safety solutions for the operating room, focusing on the prevention of medical errors. The company has developed an innovative sponge management system that integrates counting and detection capabilities, enhancing surgical efficiency and patient safety. Utilizing radio frequency identification (RFID) technology, ClearCount's platform enables quick reconciliation of sponge counts during procedures. In cases where a count does not reconcile, the SmartWand™ device assists in locating any missing sponges, further minimizing risks associated with retained surgical items. Through these advancements, ClearCount Medical Solutions aims to improve operational efficiency in surgical environments while ensuring better outcomes for patients.

ClearCut Medical

Series B in 2015
ClearCut Medical is focused on transforming cancer surgery and pathology by providing real-time feedback on surgical margins during procedures. The company addresses the challenges faced in achieving complete cancer removal while preserving healthy tissue, as a significant percentage of surgeries do not meet these objectives initially. ClearCut Medical has developed the ClearSight surgical MRI, a compact and mobile device designed for intra-operative use that offers rapid and accurate imaging, outperforming traditional histopathology methods which deliver results days after surgery. This innovation aims to enhance surgical outcomes and decrease the necessity for re-operations and follow-up treatments. Initially targeting breast-conserving surgery, the company operates within a total addressable market of $1.2 billion in the US and Europe, with plans to expand into other cancers, including lung cancer. ClearCut Medical’s business model is centered on a high-margin, single-use tissue container, distinguishing it from conventional capital equipment approaches.

Giraffic

Series A in 2013
Giraffic, Inc. provides video-on-demand (VoD) streaming acceleration technology that enables online content providers to deliver high definition (HD) VoD and other rich media. Its technology enables to retrieve data from multiple sources simultaneously in random order. The company’s video acceleration end-user application eliminates re-buffering pauses during video playback time. It enables media companies and content distributors to deliver media assets on demand in HD; supports games and software download platforms; and enables social networks and video sharing sites to store and share high-definition videos and images. The company offers its product through cloud. Giraffic, Inc. was founded in 2008 and is based in Tel-Aviv, Israel.

Cellrox

Series A in 2013
Cellrox Ltd. is a Tel-Aviv-based company founded in 2011 that specializes in mobile virtualization solutions. The company’s flagship product, Thinvisor, is a lightweight platform that allows multiple independent and secure virtual mobile instances to operate simultaneously on a single device. This technology is designed to facilitate the adoption of smartphones and tablets within corporate IT environments by providing a customized and secure mobile experience for employees. By enabling the co-hosting of separate virtual environments, Cellrox helps organizations maintain privacy and control over sensitive information while mitigating corporate risk associated with mobile device usage.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.